Perspectives High-Cost Therapy Profile: May Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV) High Cost Therapy Profile Gene therapy/Hematology Fidanacogene elaparvovec-dzkt...

PUBLICATIONS FDA Decisions Expected: March 2025 Your monthly synopsis of new drugs expected to hit the market February 14, 2025 Drug pipeline for March 2025 At Prime Therapeutics (Prime), we have...

publications FDA Decisions Expected Drug pipeline for November 2024 October 14, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have...

publications High Cost Therapy Profile: November 2024 Zenocutuzumab Intravenous (IV) November 20, 2024 Oncology Proposed indications Pancreatic ductal adenocarcinoma (PDAC) and non–small...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

Managed Healthcare Executive

Read Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

USA Today

Reuters

Insider